by | Jul 21, 2024 | Publications
Br J Haematol. 2024 Jul 19. doi: 10.1111/bjh.19627. Online ahead of print. ABSTRACT The growing use of frontline lenalidomide treatment in multiple myeloma (MM) is increasing the proportion of lenalidomide-refractory patients, which may limit the efficacy of...
by | Jul 11, 2024 | Publications
Blood. 2024 Jul 11;144(2):239. doi: 10.1182/blood.2024025274. NO ABSTRACT PMID:38990539 | DOI:10.1182/blood.2024025274
by | Jul 11, 2024 | Publications
J Palliat Med. 2024 Jul 11. doi: 10.1089/jpm.2023.0530. Online ahead of print. ABSTRACT Background: Prior studies reveal a lack of illness understanding and prognostic awareness among patients with hematological malignancies. We evaluated prognostic awareness and...
by | Jul 11, 2024 | Publications
Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-0117. Online ahead of print. ABSTRACT PURPOSE: TIGIT blockade in our ex vivo models of bone marrow (BM) reduced the number of malignant plasma cells (PCs) in only half of patients with multiple myeloma (MM)....
by | Jul 11, 2024 | Publications
Blood. 2024 Jul 11;144(2):129-131. doi: 10.1182/blood.2024024869. NO ABSTRACT PMID:38990540 | DOI:10.1182/blood.2024024869
by | Jul 11, 2024 | Publications
Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285470. Online ahead of print. ABSTRACT Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized by a...
